메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Vietnam's Visionary Leaders Redefine Success at the Asia Pacific Enterprise Awards 2025

HO CHI MINH CITY, Vietnam, Oct. 10, 2025 -- Vietnam's most visionary leaders and trailblazing enterprises took center stage at the Asia Pacific Enterprise Awards (APEA) 2025 Vietnam, held on 9 October 2025 at the GEM Center, Ho Chi Minh City. Organized by leading regional NGO Enterprise Asia, the prestigious awards program honored businesses and business leaders who are reshaping industries, embracing innovation, and driving sustainable growth. With the theme 'Showcasing Future-Ready Enterprises', this year's APEA celebrated organizations and leaders who are future-proofing the
- 김갑성 기자
- 2025-10-10 15:43
Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the CMIC-III Less Invasive Study

Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a major Cardiology Congress Via Less Invasive Approach, more Cardiologists could implant out-patient Additional studies expanding indications and level of evidence are planned next ZUG, Switzerland, Oct. 10, 2025 -- Berlin Heals Holding AG, a leading clinical-stage medical device company focused on revolutionizing the care of Heart Failure with a first of its kind durable treatment, today announced it has completed enrollment in the First-In-Huma
- 김갑성 기자
- 2025-10-10 15:00
Health in Your Hands? Asia's Top Health Experts Say 'Yes' and Reveal How

[ 메디채널 김갑성 기자 ] Over 100 healthcare leaders from 11 countries/regions convene at APSMI Summit to advance consumer-led self-care in healthcare. The Summit highlights the importance of empowering individuals with knowledge and tools to support resilient health systems. BALI, Indonesia, Oct. 10, 2025 -- More than 100 healthcare leaders from 11 Asia-Pacific countries and regions gathered at the Asia Pacific Self-Medication Industry (APSMI) Summit 2025 in Bali to accelerate self-care solutions for the region. With the theme "Self-Care in Healthcare: From Shared Vis
- 김갑성 기자
- 2025-10-10 14:43
Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan

TOKYO, Oct. 10, 2025 -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (development code: RE-021) for IgA nephropathy in Japan. The primary endpoint evaluated was the urine protein creatinine ratio (24-hour urine collection) at 36 weeks and data have now been collected for all eligible patients. Renalys will proceed with analyses of efficacy and safety through 36 weeks of treatment, as well as comparisons with global Phase III trial resu
- 김갑성 기자
- 2025-10-10 14:00
IHH Healthcare launches Global Incubator to fuel game-changing innovation

[ 메디채널 김갑성 기자 ] By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthcare ecosystem. "Through this Global Incubator Programme, we are expanding our innovation drive to support early-stage healthcare innovators, empowering them to develop solutions that can transform patient care. At IHH Healthcare, we catalyse next-level care through meaningful innovation, strategic partnerships and powerful synergies. By providing access to our extensive network, clinical expertise, and resourc
- 김갑성 기자
- 2025-10-10 13:09
ACROBiosystems and Partners Conclude OrganoAsia 2025

Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization SEOUL, South Korea, Oct. 10, 2025 -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for org
- 김갑성 기자
- 2025-10-10 09:32
ACROBiosystems and Partners Conclude OrganoAsia 2025

- Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for organoid technol
- 김갑성 기자
- 2025-10-10 09:21
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 10, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This top-tier rating by MSCI, a premier global data provider of ESG ratings and research, places WuXi Biologics among an elite group of companies globally recognized for outstanding ESG performance, and acknowledges the company's strong leadership in advocating sustainability, particularly in the key areas of clim
- 김갑성 기자
- 2025-10-10 08:30
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON, South Korea, Oct. 10, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
- 김갑성 기자
- 2025-10-10 06:56
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

[ 메디채널 김갑성 기자 ] New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer's disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex s
- 김갑성 기자
- 2025-10-10 05:23

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분